Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Closed 03-21 15:00:00

8.10

-0.11

-1.34%

High8.26	Low8.10	Vol2.39M
Open8.19	D1 Closing8.21	Amplitude1.95%
Mkt Cap8.40B	Tradable Cap5.76B	Total Shares1.04B
T/O19.53M	T/O Rate0.34%	Tradable Shares711.00M
P/B3.57	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"688505","market":"SH","secType":"STK","nameCN":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.","latestPrice":8.1,"timestamp":1742540400000,"preClose":8.21,"halted":0,"volume":2393240,"delay":0,"changeRate":-0.0134,"floatShares":711000000,"shares":1036999999,"eps":0.1015,"marketStatus":"Closed","change":-0.11,"latestTime":"03-21 15:00:00","open":8.19,"high":8.26,"low":8.1,"amount":19532500,"amplitude":0.0195,"askPrice":8.11,"askSize":86,"bidPrice":8.1,"bidSize":132,"shortable":0,"etf":0,"ttmEps":0.1015,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1742779800000},"marketStatusCode":5,"adr":0,"adjPreClose":8.21,"symbolType":"stock_kcb","openAndCloseTimeList":[[1742520600000,1742527800000],[1742533200000,1742540400000]],"highLimit":9.03,"lowLimit":7.39,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1036572100,"isCdr":false,"pbRate":3.57,"roa":"--","peRate":79.802956,"roe":"3.66%","epsLYR":0.11,"committee":0.098738,"marketValue":8396000000,"turnoverRate":0.0034,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2025-03-24.","afterMarket":{"amount":0,"volume":0,"close":8.1,"buyVolume":0,"sellVolume":0,"time":1742542438142,"indexStatus":"Closed 03-21 15:30:00","preClose":8.21},"hkstockBrief":{"symbol":"01349","market":"HK","secType":"STK","nameCN":"FUDANZHANGJIANG","latestPrice":2.65,"timestamp":1742544503028,"preClose":2.76,"halted":0,"volume":3566000,"delay":0,"premium":"-69.46"},"floatMarketCap":5756000000},"requestUrl":"/m/hq/s/688505","defaultTab":"news","newsList":[{"id":"2519484283","title":"Fudan-Zhangjiang Bio-Pharmaceutical Enrolls First Patient in Bladder Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2519484283","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519484283?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 15:10","pubTimestamp":1741936241,"startTime":"0","endTime":"0","summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's  has enrolled the first patient in the confirmatory clinical trial of its aminolevulinic acid hydrochloride granules, a Thursday filing with the Hong Kong bourse said.The product is being tested for the visualization of non-muscular invasive bladder cancer during the transurethral resection of the bladder tumor.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK1191","688505","01349"],"gpt_icon":0},{"id":"2514143344","title":"Fudan-Zhangjiang Bio-Pharmaceutical's 2024 Profit Plunges 63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514143344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514143344?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 18:43","pubTimestamp":1740739386,"startTime":"0","endTime":"0","summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's  attributable profit fell 63% to 39.7 million yuan in 2024 from 108.6 million yuan in 2023, according to a Thursday filing with the Hong Kong Exchange.Basic earnings per share at the pharmaceutical company decreased 64% to 0.04 yuan from 0.11 yuan in the previous year.Revenue declined 17% to 709.4 million yuan from 850.7 million yuan a year earlier.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","01349","688505","BK1191"],"gpt_icon":0},{"id":"2514774248","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical FY Revenue RMB 709.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514774248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514774248?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 19:11","pubTimestamp":1740654660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX4D5DC0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688505","BK0239"],"gpt_icon":0},{"id":"2504788160","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees FY Unaudited Net Profit Attributable RMB35 Million To RMB52 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2504788160","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504788160?lang=en_us&edition=full_marsco","pubTime":"2025-01-17 23:36","pubTimestamp":1737128166,"startTime":"0","endTime":"0","summary":"Jan 17 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd <688505.SS>::*SEES  UNAUDITED NET PROFIT ATTRIBUTABLE RMB35 MILLION TO RMB52 MILLION FOR YEAR*Further company coverage: 688505.SS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250117:nRSD4Tfz46:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688505","BK0239"],"gpt_icon":0},{"id":"2504154320","title":"Fudan-Zhangjiang Bio-Pharma Expects Up to 68% Lower Net Profit in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2504154320","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504154320?lang=en_us&edition=full_marsco","pubTime":"2025-01-17 20:15","pubTimestamp":1737116139,"startTime":"0","endTime":"0","summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical  expects net profit attributable to shareholders in the range of 35 million yuan and 52 million yuan in 2024, 52% to 68% lower than 108.6 million yuan logged in 2023, a Friday Hong Kong bourse filing said.The pharmaceutical company attributed the expected reduction in profit to an increase in research and development expenses, additional expenses due to scaling up production processes for two of its projects, and getting a new subsidiary operational.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688505","01349","BK1191"],"gpt_icon":0},{"id":"2504307591","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees  Unaudited Net Profit Attributable RMB35 Mln to RMB52 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2504307591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504307591?lang=en_us&edition=full_marsco","pubTime":"2025-01-17 18:49","pubTimestamp":1737110977,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250117:nFWN3OD0MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688505"],"gpt_icon":0},{"id":"2501671083","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical-  Subscription of Structured Deposit Product for RMB200 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2501671083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501671083?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 16:46","pubTimestamp":1736325999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nFWN3O4092:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688505"],"gpt_icon":0},{"id":"2500970193","title":"BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Subscribes RMB200 Mln Structured Deposit Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2500970193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500970193?lang=en_us&edition=full_marsco","pubTime":"2025-01-03 18:22","pubTimestamp":1735899778,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Subscribes RMB200 Mln Structured Deposit ProductJan 3  - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 688505.SS:AGREED TO SUBSCRIBE FOR STRUCTURED DEPOSIT PRODUCT OF RMB200 MILLIONTO SUBSCRIBE FOR CORPORATE STRUCTURED DEPOSIT PRODUCT OF PING AN BANKFurther company coverage: 688505.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250103:nFWN3NY0QH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688505"],"gpt_icon":0},{"id":"2500164510","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical  -  to Subscribe for Corporate Structured Deposit Product of Ping an Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2500164510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500164510?lang=en_us&edition=full_marsco","pubTime":"2025-01-03 16:56","pubTimestamp":1735894572,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250103:nFWN3NY0QH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688505"],"gpt_icon":0},{"id":"2500142909","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Subscription of Structured Deposit Product of RMB200 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2500142909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500142909?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 16:41","pubTimestamp":1735807264,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nFWN3NW04Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688505","BK0239"],"gpt_icon":0},{"id":"2480020743","title":"China Accepts Shanghai Fudan-Zhangjiang Bio-Pharma's Drug Application for Obeticholic Acid Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2480020743","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480020743?lang=en_us&edition=full_marsco","pubTime":"2024-11-01 15:43","pubTimestamp":1730447031,"startTime":"0","endTime":"0","summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical  said China's state drug administrator accepted the drug application of company subsidiary Taizhou Fudan Zhangjiang Pharmaceutical.The application was for the registration and marketing authorization of obeticholic acid tablets to treat primary biliary cholangitis, according to a Friday filing with the Shanghai bourse.Shares of the pharmaceutical company closed 1% higher Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688505","BK0239"],"gpt_icon":0},{"id":"2479855771","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical -  Received Acceptance Notice by Nmpa for Abbreviated New Drug Application for Obeticholic Acid Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2479855771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479855771?lang=en_us&edition=full_marsco","pubTime":"2024-10-31 16:54","pubTimestamp":1730364852,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nFWN3M709X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688505"],"gpt_icon":0},{"id":"2478029666","title":"Fudan-Zhangjiang Bio-Pharma's Q3 Profit Slides 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478029666","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478029666?lang=en_us&edition=full_marsco","pubTime":"2024-10-25 18:16","pubTimestamp":1729851392,"startTime":"0","endTime":"0","summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's  attributable profit fell 25% year over year to 16 million yuan in the third quarter.The pharmaceutical company's earnings per share were unchanged at 0.02 yuan, according to a Friday filing with the Hong Kong Exchange.Revenue declined 24% year over year to 140.7 million yuan.Shares closed 3% higher in Hong Kong on Friday.Price : $3.02, Change: $+0.10, Percent Change: +3.42%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","01349","BK4588","BK4023","BK0239","688505","BK1191","BK4526","HKD"],"gpt_icon":0},{"id":"2469456154","title":"Fudan-Zhangjiang Bio-Pharma Enrolls First Patient in US Phase 2 Trial for Birthmark Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2469456154","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469456154?lang=en_us&edition=full_marsco","pubTime":"2024-09-24 16:09","pubTimestamp":1727165371,"startTime":"0","endTime":"0","summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical  enrolled the first patient of its phase 2 clinical trial in the US for its hemoporfin injection, according to a Tuesday filing with the Shanghai Stock Exchange.The drug is indicated for the treatment of port wine stain, a type of birthmark causing a few protrusions comprising countless dilated capillaries, and could occur anywhere in the body, according to the filing.Shares closed 5% higher in Shanghai during Tuesday's trading.Price : 6.76, Change: +0.30, Percent Change: +4.64%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688505"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-06-19","address":"上海市浦东新区张江高科技园区蔡伦路308号","stockEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0025},{"period":"3month","weight":-0.0158},{"period":"6month","weight":0.2462},{"period":"1year","weight":0.0178},{"period":"ytd","weight":0.0561}],"companyName":"上海复旦张江生物医药股份有限公司","boardCode":"AI0027","perCapita":"35761股","boardName":"医药制造业","registeredCapital":"10365万元","compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.001},{"period":"6month","weight":0.2295},{"period":"1year","weight":0.0935},{"period":"ytd","weight":0.0039}],"survey":"　　上海复旦张江生物医药股份有限公司主要从事生物医药的创新研究开发、生产制造和市场营销。主要产品为盐酸氨酮戊酸外用散、注射用海姆泊芬、抗肿瘤药物长循环盐酸多柔比星脂质体注射液等。其业务主要包括在中国从事研究、开发及销售自行开发的生物医药知识、为客户提供合约制研究、制造及出售医疗产品，以及提供其他医疗服务。公司还通过其子公司从事医疗投资管理、健康产业管理、项目投资、资产管理、投资咨询、商务咨询、医疗咨询及企业战略咨询业务。","serverTime":1742669425812,"listedPrice":8.95,"stockholders":"19870人(较上一季度增加2.03%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.,688505,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票老虎,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票老虎国际,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.行情,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票行情,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股价,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股市,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票价格,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票交易,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票购买,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}